These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 35894223)

  • 21. Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: A Case report of Pemphigus Vulgaris and a literature review.
    Calabria E; Canfora F; Mascolo M; Varricchio S; Mignogna MD; Adamo D
    Pathol Res Pract; 2022 Apr; 232():153834. PubMed ID: 35278817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab in the Management of Autoimmune Bullous Diseases: A Treatment-Resistant Case Series from a Single Central European Referral Center.
    Spałek MM; Jałowska M; Bowszyc-Dmochowska M; Dmochowski M
    Medicina (Kaunas); 2024 Feb; 60(2):. PubMed ID: 38399557
    [No Abstract]   [Full Text] [Related]  

  • 23. The pathogeneses of pemphigus and pemphigoid diseases.
    Ujiie H; Yamagami J; Takahashi H; Izumi K; Iwata H; Wang G; Sawamura D; Amagai M; Zillikens D
    J Dermatol Sci; 2021 Dec; 104(3):154-163. PubMed ID: 34916040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and safety analysis of rituximab in 146 Indian pemphigus patients: A retrospective single-center review of up to 68 months follow-up.
    De D; Bishnoi A; Handa S; Mahapatra T; Mahajan R
    Indian J Dermatol Venereol Leprol; 2020; 86(1):39-44. PubMed ID: 31089006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pemphigus in Korea: clinical manifestations and treatment protocol.
    Seo PG; Choi WW; Chung JH
    J Dermatol; 2003 Nov; 30(11):782-8. PubMed ID: 14684934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autoimmune Blistering Diseases in the Elderly: Clinical Presentations and Management.
    Kim M; Borradori L; Murrell DF
    Drugs Aging; 2016 Oct; 33(10):711-723. PubMed ID: 27738963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A retrospective cohort study reporting rituximab treatment for 33 patients with immunobullous disease.
    Watson N; Carrozzo M; Hampton P
    J Oral Pathol Med; 2021 Jan; 50(1):92-97. PubMed ID: 33184901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidemiology of autoimmune bullous diseases and therapeutic modalities during a 10 year period in Iran.
    Jowkar F; Sadati MS; Tavana S; Agah MA
    Acta Dermatovenerol Croat; 2014; 22(4):246-9. PubMed ID: 25580783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intraepithelial autoimmune blistering dermatoses: Clinical features and diagnosis.
    Montagnon CM; Tolkachjov SN; Murrell DF; Camilleri MJ; Lehman JS
    J Am Acad Dermatol; 2021 Jun; 84(6):1507-1519. PubMed ID: 33684498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The association of six autoimmune bullous diseases with thyroid disorders: a population-based study.
    Kridin K; Hübner F; Linder R; Schmidt E
    J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1826-1830. PubMed ID: 35611551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Bullous autoimmune dermatoses of the mucous membranes].
    Didona D; Hinterseher J; Eming R
    Dermatologie (Heidelb); 2022 Sep; 73(9):692-700. PubMed ID: 36006424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spectrum of autoimmune blistering dermatoses in Tunisia: an 11-year study and a review of the literature.
    Zaraa I; Kerkeni N; Ishak F; Zribi H; El Euch D; Mokni M; Osman AB
    Int J Dermatol; 2011 Aug; 50(8):939-44. PubMed ID: 21781064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autoimmune blistering diseases provoked during the treatment of chronic inflammatory disease with biologic agents: a systematic review.
    Gibson FT; Amber KT
    Int J Dermatol; 2020 May; 59(5):520-524. PubMed ID: 31631316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of autoimmune bullous diseases in Serbia: a 20-year retrospective study.
    Milinković MV; Janković S; Medenica L; Nikolić M; Reljić V; Popadić S; Janković J
    J Dtsch Dermatol Ges; 2016 Oct; 14(10):995-1005. PubMed ID: 27767273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Autoimmune blistering skin diseases: diagnostic and therapeutic approach].
    Hammers CM; Schmidt E; Zillikens D
    Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1473-7. PubMed ID: 24983196
    [No Abstract]   [Full Text] [Related]  

  • 36. Immunofluorescence testing in the diagnosis of autoimmune blistering diseases: overview of 10-year experience.
    Arbache ST; Nogueira TG; Delgado L; Miyamoto D; Aoki V
    An Bras Dermatol; 2014; 89(6):885-9. PubMed ID: 25387492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients.
    Kim MR; Kim HC; Kim SC
    Dermatology; 2011; 223(2):182-8. PubMed ID: 22025028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. State-of-the-art review of human autoimmune blistering diseases (AIBD).
    Zeng FAP; Murrell DF
    Vet Dermatol; 2021 Dec; 32(6):524-e145. PubMed ID: 34351020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score.
    Rahbar Z; Daneshpazhooh M; Mirshams-Shahshahani M; Esmaili N; Heidari K; Aghazadeh N; Hejazi P; Ghajarzadeh M; Chams-Davatchi C
    JAMA Dermatol; 2014 Mar; 150(3):266-72. PubMed ID: 24429657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autoimmune bullous diseases in Austria.
    Laimer M; Pohla-Gubo G; Kraus L; Nischler E; Bauer JW; Ahlgrimm-Siess V; Hintner H
    Dermatol Clin; 2011 Oct; 29(4):691-8. PubMed ID: 21925021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.